TY  - JOUR
AU  - Cabeza, Laura
AU  - El-Hammadi, Mazen M.
AU  - Ortiz, Raul
AU  - Cayero-Otero, Maria D.
AU  - Jimenez-Lopez, Julia
AU  - Perazzoli, Gloria
AU  - Martin-Banderas, Lucia
AU  - Baeyens, Jose M.
AU  - Melguizo, Consolacion
AU  - Prados, Jose
PY  - 2022
DO  - 10.34172/bi.2022.23433
SN  - 2228-5652
UR  - http://hdl.handle.net/10668/21817
T2  - Bioimpacts
AB  - Introduction: Paclitaxel (PTX) is a cornerstone in the treatment of breast cancer, the most common type of cancer in women. However, this drug has serious limitations, including lack of tissue-specificity, poor water solubility, and the development of...
LA  - en
PB  - Tabriz University of Medical Sciences and Health Services
KW  - Paclitaxel
KW  - PLGA
KW  - Breast cancer
KW  - Cancer stem cells
KW  - Mice xenografts
KW  - Plga-based nanoparticles
KW  - Albumin-bound paclitaxel
KW  - Tumor-targeted delivery
KW  - Drug-delivery
KW  - In-vitro
KW  - Intracellular pharmacokinetics
KW  - Blood-pressure
KW  - Ovarian-cancer
KW  - Challenges
KW  - Women
KW  - Female
KW  - Paclitaxel
KW  - Breast Neoplasms
KW  - Tubulin
KW  - Tissue Distribution
KW  - nile red
KW  - MCF-7 Cells
KW  - Solubility
KW  - Tumor Burden
KW  - Inhibitory Concentration 50
KW  - Spleen
KW  - Mice, Inbred C57BL
KW  - Antineoplastic Agents
KW  - Cell Cycle
KW  - Lung
KW  - Drug Resistance
KW  - Liver
KW  - Drug Resistance
KW  - Neoplastic Stem Cells
TI  - Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer
TY  - research article
ER  -